Date:10/31/2012

,22661,22660,07960,079(a) Restructuring plan charges include $1.7 million in severance costs and $1.0 million of facility-related costs and the associated tax impact(b) Legal charges related to a dispute(c) Adjustments to facility-related charges of $0.3 million related to restructuring plans(d) Gain on facility sale previously impaired(e) Tax associated with items (b) through (d) and a tax expense for one-time adjustments to deferred tax assetsBalance Sheet InformationPreliminarySeptember 30,September 30,June 30,201220112012Billed accounts receivable, net$
339,675$
324,763$
397,372Unbilled accounts receivable, net270,789326,726251,845Deferred revenue(341,398)(352,284)(359,714)Net receivables$
269,066$
299,205$
289,503Cash and marketable securities$
249,051$
32,488$
213,579Working capital$
381,845$
337,270$
349,204Total assets$
,542,875$
,456,121$
,535,372Short-term borrowings$
,253$
5,573$
5,003Long-term debt$
267,500$
263,752$
215,000Stockholders' equity$
588,017$
544,949$
9,675 PAREXEL International CorporationSegment InformationUnauditedThree Months EndedThree Months Ended(in thousands)September 30, 2012September 30, 2011 Clinical Research Services (CRS)Service revenue $
297,167$
235,409% of total service revenue75.3%74.8%Gross profit$
77,001$
2,659Gross margin % of service revenue25.9%26.6%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
48,351$
35,648% of total service revenue12.2%11.3%Gross profit$
8,666$
4,670Gross margin % of service revenue38.6%41.2%Perceptive Informatics (PI)Service revenue$
49,235$
43,678% of total service revenue12.5%13.9%Gross profit$
9,682$
5,232Gross margin % of service revenue40.0%34.9%Total service revenue$
394,753$
314,735Total gross profit$
5,349$
92,561Gross margin % of service revenue29.2%29.4%Revenue by GeographyThe
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
2. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
3. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
4. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
5. PAREXEL International to Present at J.P. Morgan Healthcare Conference
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. ABTCP: Internationale Krise beeinflusst den Papier- und Zellstoffmarkt, doch Brasilien investiert weiterhin in Innovationen
8. BioSpain 2012 is Larger in Terms of Internationalisation and the Number of Exhibitors, Meetings and Visitors
9. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
10. VWR International, LLC Acquires Sovereign Group
11. Ohio State Hosting International Personalized Health Care Leaders